Gregory J Tranah1, Adam Santaniello2, Stacy J Caillier2, Sandra D'Alfonso2, Filippo Martinelli Boneschi2, Stephen L Hauser2, Jorge R Oksenberg2. 1. From the California Pacific Medical Center Research Institute (G.J.T.), San Francisco, CA; Department of Neurology (A.S., S.J.C., S.L.H., J.R.O.), University of California, San Francisco; Department of Health Sciences (S.D.), UPO and Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Eastern Piedmont, Avogadro, Novara, Italy; and Department of Neuro-rehabilitation and INSPE (Institute of Experimental Neurology) (F.M.B.), Scientific Institute San Raffaele, Milan, Italy. gtranah@sfcc-cpmc.edu. 2. From the California Pacific Medical Center Research Institute (G.J.T.), San Francisco, CA; Department of Neurology (A.S., S.J.C., S.L.H., J.R.O.), University of California, San Francisco; Department of Health Sciences (S.D.), UPO and Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), University of Eastern Piedmont, Avogadro, Novara, Italy; and Department of Neuro-rehabilitation and INSPE (Institute of Experimental Neurology) (F.M.B.), Scientific Institute San Raffaele, Milan, Italy.
Abstract
OBJECTIVE: To assess the influence of common mitochondrial DNA (mtDNA) sequence variation on multiple sclerosis (MS) risk in cases and controls part of an international consortium. METHODS: We analyzed 115 high-quality mtDNA variants and common haplogroups from a previously published genome-wide association study among 7,391 cases from the International Multiple Sclerosis Genetics Consortium and 14,568 controls from the Wellcome Trust Case Control Consortium 2 project from 7 countries. Significant single nucleotide polymorphism and haplogroup associations were replicated in 3,720 cases and 879 controls from the University of California, San Francisco. RESULTS: An elevated risk of MS was detected among haplogroup JT carriers from 7 pooled clinic sites (odds ratio [OR] = 1.15, 95% confidence interval [CI] = 1.07-1.24, p = 0.0002) included in the discovery study. The increased risk of MS was observed for both haplogroup T (OR = 1.17, 95% CI = 1.06-1.29, p = 0.002) and haplogroup J carriers (OR = 1.11, 95% CI = 1.01-1.22, p = 0.03). These haplogroup associations with MS were not replicated in the independent sample set. An elevated risk of primary progressive (PP) MS was detected for haplogroup J participants from 3 European discovery populations (OR = 1.49, 95% CI = 1.10-2.01, p = 0.009). This elevated risk was borderline significant in the US replication population (OR = 1.43, 95% CI = 0.99-2.08, p = 0.058) and remained significant in pooled analysis of discovery and replication studies (OR = 1.43, 95% CI = 1.14-1.81, p = 0.002). No common individual mtDNA variants were associated with MS risk. CONCLUSIONS: Identification and validation of mitochondrial genetic variants associated with MS and PPMS may lead to new targets for treatment and diagnostic tests for identifying potential responders to interventions that target mitochondria.
OBJECTIVE: To assess the influence of common mitochondrial DNA (mtDNA) sequence variation on multiple sclerosis (MS) risk in cases and controls part of an international consortium. METHODS: We analyzed 115 high-quality mtDNA variants and common haplogroups from a previously published genome-wide association study among 7,391 cases from the International Multiple Sclerosis Genetics Consortium and 14,568 controls from the Wellcome Trust Case Control Consortium 2 project from 7 countries. Significant single nucleotide polymorphism and haplogroup associations were replicated in 3,720 cases and 879 controls from the University of California, San Francisco. RESULTS: An elevated risk of MS was detected among haplogroup JT carriers from 7 pooled clinic sites (odds ratio [OR] = 1.15, 95% confidence interval [CI] = 1.07-1.24, p = 0.0002) included in the discovery study. The increased risk of MS was observed for both haplogroup T (OR = 1.17, 95% CI = 1.06-1.29, p = 0.002) and haplogroup J carriers (OR = 1.11, 95% CI = 1.01-1.22, p = 0.03). These haplogroup associations with MS were not replicated in the independent sample set. An elevated risk of primary progressive (PP) MS was detected for haplogroup J participants from 3 European discovery populations (OR = 1.49, 95% CI = 1.10-2.01, p = 0.009). This elevated risk was borderline significant in the US replication population (OR = 1.43, 95% CI = 0.99-2.08, p = 0.058) and remained significant in pooled analysis of discovery and replication studies (OR = 1.43, 95% CI = 1.14-1.81, p = 0.002). No common individual mtDNA variants were associated with MS risk. CONCLUSIONS: Identification and validation of mitochondrial genetic variants associated with MS and PPMS may lead to new targets for treatment and diagnostic tests for identifying potential responders to interventions that target mitochondria.
Authors: Alessandro Biffi; Christopher D Anderson; Michael A Nalls; Rosanna Rahman; Akshata Sonni; Lynelle Cortellini; Natalia S Rost; Mar Matarin; Dena G Hernandez; Anna Plourde; Paul I W de Bakker; Owen A Ross; Steven M Greenberg; Karen L Furie; James F Meschia; Andrew B Singleton; Richa Saxena; Jonathan Rosand Journal: Am J Hum Genet Date: 2010-05-27 Impact factor: 11.025
Authors: Richa Saxena; Paul I W de Bakker; Karyn Singer; Vamsi Mootha; Noel Burtt; Joel N Hirschhorn; Daniel Gaudet; Bo Isomaa; Mark J Daly; Leif Groop; Kristin G Ardlie; David Altshuler Journal: Am J Hum Genet Date: 2006-05-24 Impact factor: 11.025
Authors: S Venkateswaran; K Zheng; M Sacchetti; D Gagne; D L Arnold; A D Sadovnick; S W Scherer; B Banwell; A Bar-Or; D K Simon Journal: Neurology Date: 2011-02-02 Impact factor: 9.910
Authors: Gavin Hudson; Valerio Carelli; Liesbeth Spruijt; Mike Gerards; Catherine Mowbray; Alessandro Achilli; Angela Pyle; Joanna Elson; Neil Howell; Chiara La Morgia; Maria Lucia Valentino; Kirsi Huoponen; Marja-Liisa Savontaus; Eeva Nikoskelainen; Alfredo A Sadun; Solange R Salomao; Rubens Belfort; Philip Griffiths; Patrick Yu-Wai-Man; Rene F M de Coo; Rita Horvath; Massimo Zeviani; Hubert J T Smeets; Antonio Torroni; Patrick F Chinnery Journal: Am J Hum Genet Date: 2007-06-04 Impact factor: 11.025
Authors: Graham R Campbell; Iryna Ziabreva; Amy K Reeve; Kim J Krishnan; Richard Reynolds; Owen Howell; Hans Lassmann; Doug M Turnbull; Don J Mahad Journal: Ann Neurol Date: 2010-11-08 Impact factor: 10.422
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422
Authors: Leonardo Lorente; Ruth Iceta; María M Martín; Esther López-Gallardo; Jordi Solé-Violán; José Blanquer; Lorenzo Labarta; César Díaz; Juan María Borreguero-León; Alejandro Jiménez; Julio Montoya; Eduardo Ruiz-Pesini Journal: PLoS One Date: 2013-09-12 Impact factor: 3.240
Authors: Carlos A Vaz Fragoso; Todd M Manini; John A Kairalla; Thomas W Buford; Fang-Chi Hsu; Thomas M Gill; Stephen B Kritchevsky; Mary M McDermott; Jason L Sanders; Steven R Cummings; Gregory J Tranah Journal: Exp Gerontol Date: 2018-12-01 Impact factor: 4.032
Authors: Roel P J Bevers; Maria Litovchenko; Adamandia Kapopoulou; Virginie S Braman; Matthew R Robinson; Johan Auwerx; Brian Hollis; Bart Deplancke Journal: Nat Metab Date: 2019-12-09
Authors: Jayden A Smith; Alexandra M Nicaise; Rosana-Bristena Ionescu; Regan Hamel; Luca Peruzzotti-Jametti; Stefano Pluchino Journal: Front Cell Dev Biol Date: 2021-07-09
Authors: Anne I Boullerne; Mitchell T Wallin; William J Culpepper; Heidi Maloni; Elizabeth A Boots; Dagmar M Sweeney; Douglas L Feinstein Journal: Mult Scler Relat Disord Date: 2021-08-02 Impact factor: 4.808
Authors: Thomas W Buford; Todd M Manini; John A Kairalla; Mary M McDermott; Carlos A Vaz Fragoso; Haiying Chen; Roger A Fielding; Abby C King; Anne B Newman; Gregory J Tranah Journal: J Am Heart Assoc Date: 2018-09-18 Impact factor: 5.501